126 related articles for article (PubMed ID: 38581923)
1. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide.
Liu C; Long Q; Yang H; Yang H; Tang Y; Liu B; Zhou Z; Yuan J
Biomed Pharmacother; 2024 May; 174():116535. PubMed ID: 38581923
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
3. Neprilysin Inhibition Promotes Skeletal Growth via the CNP/NPR-B Pathway.
Hakata T; Ueda Y; Yamashita T; Yamauchi I; Kosugi D; Sugawa T; Fujita H; Okamoto K; Fujii T; Taura D; Yasoda A; Akiyama H; Inagaki N
Endocrinology; 2024 May; 165(7):. PubMed ID: 38752331
[TBL] [Abstract][Full Text] [Related]
4. Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.
Liu S; Wang Y; Lu S; Hu J; Zeng X; Liu W; Wang Y; Wang Z
Life Sci; 2021 Feb; 266():118877. PubMed ID: 33310048
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
[TBL] [Abstract][Full Text] [Related]
7. Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar.
Martínez-Falguera D; Aranyó J; Teis A; Ferrer-Curriu G; Monguió-Tortajada M; Fadeuilhe E; Rodríguez-Leor O; Díaz-Güemes I; Roura S; Villuendas R; Sarrias A; Bazan V; Delgado V; Bayes-Genis A; Bisbal F; Gálvez-Montón C
Circ Arrhythm Electrophysiol; 2024 May; 17(5):e012517. PubMed ID: 38666379
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
[TBL] [Abstract][Full Text] [Related]
9. Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
Thonsgaard S; Prickett TCR; Hansen LH; Wewer Albrechtsen NJ; Andersen UØ; Terzic D; Plomgaard P; Gustafsson F; Goetze JP; Mark PD
Clin Chem; 2022 May; 68(5):713-720. PubMed ID: 35175317
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
11. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
13. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
[TBL] [Abstract][Full Text] [Related]
14. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
15. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Ibrahim NE; McCarthy CP; Shrestha S; Gaggin HK; Mukai R; Szymonifka J; Apple FS; Burnett JC; Iyer S; Januzzi JL
J Am Coll Cardiol; 2019 Mar; 73(11):1273-1284. PubMed ID: 30898202
[TBL] [Abstract][Full Text] [Related]
16. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Nishio H; Ishii A; Yamada H; Mori KP; Kato Y; Ohno S; Handa T; Sugioka S; Ishimura T; Ikushima A; Inoue Y; Minamino N; Mukoyama M; Yanagita M; Yokoi H
Nephrol Dial Transplant; 2023 Oct; 38(11):2517-2527. PubMed ID: 37202215
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway.
Liang W; Xie BK; Ding PW; Wang M; Yuan J; Cheng X; Liao YH; Yu M
Front Pharmacol; 2021; 12():727838. PubMed ID: 34603042
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation.
Li LY; Lou Q; Liu GZ; Lv JC; Yun FX; Li TK; Yang W; Zhao HY; Zhang L; Bai N; Zhan CC; Yu J; Zang YX; Li WM
Eur J Pharmacol; 2020 Aug; 881():173120. PubMed ID: 32325147
[TBL] [Abstract][Full Text] [Related]
20. Ivermectin ameliorates acute myocarditis via the inhibition of importin-mediated nuclear translocation of NF-κB/p65.
Gao X; Xuan Y; Zhou Z; Chen C; Wen Wang D; Wen Z
Int Immunopharmacol; 2024 May; 133():112073. PubMed ID: 38636372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
